Centre for Cancer Research

Oncogenic signalling publications

2009
Adams TE, Koziolek EJ, Hoyne PH, Bentley JD, Lu L, Lovrecz G, Ward CW, Lee FT, Scott AM, Nash AD, Rothacker J, Nice EC, Burgess AW, Johns TG (2009) A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. Growth Factors 27:141-154.

Gan HK, Lappas M, Cao DX, Cvrljevic A, Scott AM, Johns TG (2009) Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumor vascular normalization. J Cell Mol Med (in press: available online 11 May 2009).

Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, Orchard SG, Clayton AH, Nice EC, Rothacker J, Catimel B, Cavenee WK, Old LJ, Stockert E, Ritter G, Adams TE, Hoyne PA, Wittrup D, Chao G, Cochran JR, Luo C, Lou M, Huyton T, Xu Y, Fairlie WD, Yao S, Scott AM, Johns TG (2009) Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A 106:5082-5087.

Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG (2009) The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11:448-458, 2 p following 458.

2008
Ashley DM, Riffkin CD, Lovric MM, Mikeska T, Dobrovic A, Maxwell JA, Friedman HS, Drummond KJ, Kaye AH, Gan HK, Johns TG and Hawkins CJ (2008). In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs .  Br J Cancer 99: 294-304.

Zhang H, Sunnarborg SW, McNaughton KK, Johns TG, Lee DC and Faber JE (2008)   Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling. Circ Res, 102:1275-85.


2007
Clayton AHA, Tavarnesi ML and JohnsTG (2007). Unligated EGFR forms higher-order oligomers within micro-clusters on A431 cells that are sensitive to tyrosine-kinase inhibitor binding . Biochemistry 46: 4589-97.

Gan HK, Walker F, Burgess AW, Scott AM and Johns TG (2007) The EGFR tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers: Implications for combination therapy with mAb 806. JBC 282: 2840-2850.

Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM and Furnari FB (2007) The efficacy of EGFR-specific antibodies against glioma xenografts is influenced by receptor levels, activation status and heterodimerization. Clinical Cancer Research 13: 1911-1925.

Scott AM, Lee F-T, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AMT,  Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Brechbie MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ (2007) A phase i clinical trial with monoclonal antibody Ch806 targeting transitional state and mutant epidermal growth factor receptor. PNAS 104: 4071-4076.

Perera RM, Zoncu R, Johns TG, Pypaert, Lee FT, Mellman I, Old, Toomre DK and Scott AM (2007) Internalization, Intracellular Trafficking, and Biodistribution of Monoclonal Antibody 806: A Novel Anti–Epidermal Growth Factor Receptor Antibody. Neoplasia 9:1099-110.


2006
Ellis AG, Doherty MM, Walker F, Weinstock J, Nerrie M, Vitali AA, Murphy R, Johns TG, Scott AM, Levitzki A, McLachlan G, Webster LK, Burgess AW and Nice EC (2006)  Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem.  Pharmacol. 14: 1422-34.

Liu B, Chen H, Johns TG and Neufeld AH (2006) Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J Neurosci. 26: 7532-40.

Wade JD, Hojo K, Kawasaki K, Johns TG, Catimel B, Rothacker J and Nice EC (2006). An automated peptide and protein thiazolidine coupling chemistry for biosensor immobilisation in a unique n-terminal orientation. Analytical Biochemistry, 348: 315-317.


2005
Johns TG, Mellman I, Cartwright GA, Ritter G, Old LJ, Burgess AW and Scott AM (2005). The anti-tumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J. 19: 780-782.

Lee F-T, Mountain AJ, Kelly M, Hall C, Rigopoulos A, Johns TG, Smyth FE, Brechbiel MW, Nice EC, Burgess AW and Scott AM (2005). Enhanced efficacy of radioimmunotherapy with ⁹⁰Y-CHX-A"-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signalling with EGFR tyrosine kinase inhibitor AG1478. Clinical Cancer Research, 11: 7080s-7086s.

Perera RM, Narita Y, Furnari FB, Luwor RB, Burgess AW, Old LJ, Cavenee WK, Scott AM and Johns TG (2005) A novel EGFR antibody that displays synergistic anti-tumor activity when combined with conventional EGFR therapeutics.  Clinical Cancer Research 11: 6390-6399.

Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee F-T, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ and Scott AM (2005) Engineering and characterization of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.  Br. J. Cancer, 92: 1069 – 1077.

Scott AM, Liu Z, Murone C, Johns TG, MacGregor D, Smyth FE, Lee F-T, Cebon JS, Davis ID, Hopkins W,  Mountain AJ, Rigopoulos A, Hanai N, Old LJ  Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.  Cancer Immun [serial online] 5:3 ww.cancerimmunity.org/v5p3/041221.htm.

Whitson KB, Red ML, Whitson SR, McCoy A, Vitali AA, Walker F, Johns TG, Beth AH and Staros JV (2005).  Functional effects of selective glycosylation at Asn-579 of the epidermal growth factor receptor. Biochemistry, 44: 14920-14931.


2004
Faux MC, Ross JL, Meeker C, Johns TG, Ji H, Simpson RJ, Layton MJ and Burgess AW (2004). Restoration of full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion. J.Cell Sci  117: 427-39.

Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, Kim Y-S, Rothacker J, Nice EC, Walker F, Ritter G, Jungbluth AA, Old LJ, Ward CW, Burgess AW, Wittrup KD, and Scott, AM Identification of the epitope for the EGFR-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.  JBC, 279: 30375-30384.

Luwor RB, Zhu H-J, Walker F, Vitali AA, Perera RM, Burgess AW, Scott AM and Johns TG (2004) The tumor specific de2-7 epidermal growth factor receptor (EGFR) confers increased survival in BaF/3 cells via a PI-3 kinase dependent mechanism.  Oncogene 23: 6095-6104.

Walker F, Orchard SG, Jorissen RN, Hall NE, Zhang H-H, Hoyne PA, Adams TE, Johns TG, Ward CW, Garrett TPJ, Zhu H-H, Nerrie M, Scott AM, Nice EC, and Burgess AW (2004)  CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.  JBC, 279: 22387–22398.

The article above was featured on the Science, Signal Transduction Knowledge Environment Webpage.  (Sci. STKE, 20 July 2004, Vol. 2004, Issue 242, p. tw259 [DOI: 10.1126/stke.2422004TW259])


2003
Clements GS, ReidHH, Beddoe T, Tynan FE, Perugini MA, Johns TG, Bernard CCA and Rossjohn J (2003).  The crystal structure of  myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis  PNAS 100: 11059-11064.

Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Old LJ, Nice EC, Burgess AW and Scott AM (2003) Anti-tumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the epidermal growth factor receptor (EGFR) inhibitor AG1478. PNAS, 100: 15871-15876.

Jungbluth AA,  Stockert E, Huang H-JS, Collins VP, Coplan, K, Iversen K, Kolb D, Johns TG, Scott AM, Gullick WJ, Ritter G, Cohen L, Cavanee WK, Old LJ (2003) A monoclonal antibody recognizing human cancers with amplification/over-expression of the human epidermal growth factor receptor, PNAS 100: 639-644.

Liu Z, Panousis C, Smyth FE, Murphy R, Wirth V, Cartwright GA, Johns TG and Scott AM (2003) Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses (2003). Hybridoma and Hybridomics, 22: 219-228.